<p>麒麟控股公司（东京证券交易所代码：2503）再次成为焦点，因为其子公司京华生物与 Cowellnex 和 Metagen 合作，研究针对日本消费者的肠道微生物群检测和个性化食品推荐算法。</p>
<p>查看我们对麒麟控股公司的最新分析。</p>
<p>肠道健康合作伙伴关系与 30 天股价回报率 8.44% 和 90 天股价回报率 10.62% 并行，而 1 年总股东回报率 29.85% 则表明势头在增强而非减弱。</p>
<p>如果您关注个性化健康的趋势，现在可能是查看其他通过我们的 6 只医疗保健 AI 股票筛选器塑造未来医学的机会。</p>
<p>在过去一年中，股价上涨近 30%，接近¥2,644 的分析师目标价，但显示出约 43% 的内在折扣，您不得不问：麒麟是否仍被低估，还是市场已经在定价未来的增长？</p>
<h2>14.2 倍的市盈率：这合理吗？</h2>
<p>在 14.2 倍的市盈率下，麒麟控股公司看起来比许多同行便宜，即使在最近将股价推高至¥2,589 之后。</p>
<p>市盈率将当前股价与每股收益进行比较，是快速了解投资者为每单位利润支付多少的方式。对于一个涵盖啤酒、软饮料、健康科学和制药的企业来说，盈利能力通常比短期收入波动更重要。</p>
<p>在这里，当前的 14.2 倍市盈率低于同行平均的 20.2 倍和亚洲饮料行业平均的 17.4 倍。这表明市场对麒麟的盈利评估比许多可比公司更为保守。根据我们基于回归的公允市盈率估算 23.3 倍，这一差距甚至更大，表明如果对盈利质量和增长的情绪与该公允倍数一致，市场可能会向该水平靠拢。</p>
<p>探索麒麟控股公司的 SWS 公允比率</p>
<p><strong>结果：14.2 倍的市盈率（被低估）</strong></p>
<p>然而，如果盈利减弱或个性化健康的推动未能获得消费者和监管机构的认可，故事可能会迅速改变。</p>
<p>了解麒麟控股公司叙述的关键风险。</p>
<h2>另一种观点，现金流故事说了什么？</h2>
<p>基于盈利的观点已经看起来支持，但我们的 DCF 模型进一步表明，麒麟的每股价值约为¥4,545，而当前为¥2,589。这意味着股票交易存在较大折扣，因此引发了市场是否过于谨慎的问题。</p>
<p>了解 SWS DCF 模型如何得出其公允价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f4e95d4-3172-4786-9308-dd44ed79961b/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f4e95d4-3172-4786-9308-dd44ed79961b/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTA3"/></p>
<p>截至 2026 年 3 月的 2503 折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看麒麟控股公司）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 24 只高质量被低估的股票。如果您保存了筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
<h2>下一步</h2>
<p>如果这一切看起来像是一个复杂的图景，请花点时间自己查看数字，并在决定这对您意味着什么之前权衡 5 个关键回报和 1 个重要警告信号。</p>
<h2>寻找更多投资想法？</h2>
<p>如果您在考虑下一步行动，请不要只停留在单一公司。利用可用工具扩大您的机会范围。</p>
<ul>
<li>通过扫描我们 24 只高质量被低估的股票列表，寻找潜在的错误定价，这些股票将盈利能力与更温和的市场预期相结合。</li>
<li>通过审查 20 只可能帮助稳定定期现金支付投资组合的股息堡垒，增强您的收入策略。</li>
<li>通过考虑 51 只低风险得分的抗压股票，降低投资组合压力，这些股票在稳定性和财务韧性方面表现良好。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3>估值复杂，但我们在这里简化它。</h3>
<p>通过我们的详细分析，发现麒麟控股公司是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

2503

4151

<p>麒麟控股公司（TSE:2503）因其子公司京华生物与 Cowellnex 和 Metagen 合作开发肠道微生物健康解决方案而受到关注。该公司在过去 30 天内股价上涨了 8.44%，过去一年回报率为 29.85%。麒麟的市盈率为 14.2 倍，低于行业平均水平，相较于其估计的每股公允价值¥4,545，麒麟似乎被低估。然而，如果盈利下降或健康项目进展不顺，风险仍然存在。投资者被鼓励进一步探索被低估股票的机会</p>

<p>Kirin Holdings Company (TSE:2503) is back in focus after its subsidiary Kyowa Kirin joined Cowellnex and Metagen to research gut microbiota based tests and personalized food recommendation algorithms for Japanese consumers.</p>
<div class="lb-trans"><p>麒麟控股公司（东京证券交易所代码：2503）再次成为焦点，因为其子公司京华生物与 Cowellnex 和 Metagen 合作，研究针对日本消费者的肠道微生物群检测和个性化食品推荐算法。</p>
</div><p>See our latest analysis for Kirin Holdings Company.</p>
<div class="lb-trans"><p>查看我们对麒麟控股公司的最新分析。</p>
</div><p>The gut health partnership sits alongside a 30 day share price return of 8.44% and a 90 day share price return of 10.62%, while the 1 year total shareholder return of 29.85% points to momentum that has been building rather than fading.</p>
<div class="lb-trans"><p>肠道健康合作伙伴关系与 30 天股价回报率 8.44% 和 90 天股价回报率 10.62% 并行，而 1 年总股东回报率 29.85% 则表明势头在增强而非减弱。</p>
</div><p>If this move into personalized health is on your radar, it could be a good moment to see what else is shaping the future of medicine through our screener of 6 healthcare AI stocks.</p>
<div class="lb-trans"><p>如果您关注个性化健康的趋势，现在可能是查看其他通过我们的 6 只医疗保健 AI 股票筛选器塑造未来医学的机会。</p>
</div><p>With the shares up almost 30% over the past year and trading close to a ¥2,644 analyst target yet showing an intrinsic discount of about 43%, you have to ask: is Kirin still undervalued, or is the market already pricing in future growth?</p>
<div class="lb-trans"><p>在过去一年中，股价上涨近 30%，接近¥2,644 的分析师目标价，但显示出约 43% 的内在折扣，您不得不问：麒麟是否仍被低估，还是市场已经在定价未来的增长？</p>
</div><h2>Price-to-Earnings of 14.2x: Is it justified?</h2>
<div class="lb-trans"><h2>14.2 倍的市盈率：这合理吗？</h2>
</div><p>On a P/E of 14.2x, Kirin Holdings Company looks cheaper than many peers, even after the recent move that has taken the share price to ¥2,589.</p>
<div class="lb-trans"><p>在 14.2 倍的市盈率下，麒麟控股公司看起来比许多同行便宜，即使在最近将股价推高至¥2,589 之后。</p>
</div><p>P/E compares the current share price with earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a business spanning beer, soft drinks, health science and pharmaceuticals, earnings power often matters more to investors than short term revenue swings.</p>
<div class="lb-trans"><p>市盈率将当前股价与每股收益进行比较，是快速了解投资者为每单位利润支付多少的方式。对于一个涵盖啤酒、软饮料、健康科学和制药的企业来说，盈利能力通常比短期收入波动更重要。</p>
</div><p>Here, the current 14.2x P/E sits below the peer average of 20.2x and the Asian Beverage industry average of 17.4x. This suggests the market is valuing Kirin’s earnings more conservatively than many comparable names. Against an estimated fair P/E of 23.3x from our regression based fair ratio work, that gap is even wider and points to a level the market could potentially gravitate toward if sentiment on earnings quality and growth were to align with that fair multiple.</p>
<div class="lb-trans"><p>在这里，当前的 14.2 倍市盈率低于同行平均的 20.2 倍和亚洲饮料行业平均的 17.4 倍。这表明市场对麒麟的盈利评估比许多可比公司更为保守。根据我们基于回归的公允市盈率估算 23.3 倍，这一差距甚至更大，表明如果对盈利质量和增长的情绪与该公允倍数一致，市场可能会向该水平靠拢。</p>
</div><p>Explore the SWS fair ratio for Kirin Holdings Company</p>
<div class="lb-trans"><p>探索麒麟控股公司的 SWS 公允比率</p>
</div><p><strong>Result: Price-to-Earnings of 14.2x (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：14.2 倍的市盈率（被低估）</strong></p>
</div><p>However, the story can shift quickly if earnings soften or if the personalized health push fails to gain traction with consumers and regulators.</p>
<div class="lb-trans"><p>然而，如果盈利减弱或个性化健康的推动未能获得消费者和监管机构的认可，故事可能会迅速改变。</p>
</div><p>Find out about the key risks to this Kirin Holdings Company narrative.</p>
<div class="lb-trans"><p>了解麒麟控股公司叙述的关键风险。</p>
</div><h2>Another View, What Does The Cash Flow Story Say?</h2>
<div class="lb-trans"><h2>另一种观点，现金流故事说了什么？</h2>
</div><p>The earnings based view already looks supportive, but our DCF model goes further and suggests Kirin could be worth around ¥4,545 per share, compared with the current ¥2,589. That implies the shares are trading at a steep discount, so it raises the question of whether the market is being overly cautious.</p>
<div class="lb-trans"><p>基于盈利的观点已经看起来支持，但我们的 DCF 模型进一步表明，麒麟的每股价值约为¥4,545，而当前为¥2,589。这意味着股票交易存在较大折扣，因此引发了市场是否过于谨慎的问题。</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其公允价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f4e95d4-3172-4786-9308-dd44ed79961b/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTA3" alt="" original-src="https://images.simplywall.st/company/4f4e95d4-3172-4786-9308-dd44ed79961b/chart/dcf?date=2026-03-07"/></p>
<p>2503 Discounted Cash Flow as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月的 2503 折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kirin Holdings Company for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 24 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看麒麟控股公司）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 24 只高质量被低估的股票。如果您保存了筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>If this all feels like a mixed picture, take a moment now to look through the numbers yourself and weigh up the 5 key rewards and 1 important warning sign before you decide what it means for you.</p>
<div class="lb-trans"><p>如果这一切看起来像是一个复杂的图景，请花点时间自己查看数字，并在决定这对您意味着什么之前权衡 5 个关键回报和 1 个重要警告信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If you are weighing up your next move, do not stop at a single company. Use the tools available to widen your opportunity set.</p>
<div class="lb-trans"><p>如果您在考虑下一步行动，请不要只停留在单一公司。利用可用工具扩大您的机会范围。</p>
</div><ul>
<li>Target potential mispricings by scanning our list of 24 high quality undervalued stocks that pair earnings power with more modest market expectations.</li>
<li>Strengthen your income playbook by reviewing 20 dividend fortresses that could help anchor a portfolio with regular cash payouts.</li>
<li>Dial down portfolio stress by considering 51 resilient stocks with low risk scores that score well on stability and financial resilience.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描我们 24 只高质量被低估的股票列表，寻找潜在的错误定价，这些股票将盈利能力与更温和的市场预期相结合。</li>
<li>通过审查 20 只可能帮助稳定定期现金支付投资组合的股息堡垒，增强您的收入策略。</li>
<li>通过考虑 51 只低风险得分的抗压股票，降低投资组合压力，这些股票在稳定性和财务韧性方面表现良好。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里简化它。</h3>
</div><p>Discover if Kirin Holdings Company might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现麒麟控股公司是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

在新的肠道微生物健康合作之后，评估麒麟控股公司（TSE:2503）的估值